Bruker Corporation (NASDAQ:BRKR) Position Raised by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP increased its stake in shares of Bruker Corporation (NASDAQ:BRKR) by 7.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 944,553 shares of the medical research company’s stock after buying an additional 66,344 shares during the period. Dimensional Fund Advisors LP’s holdings in Bruker Corporation were worth $22,034,000 as of its most recent filing with the SEC.
Several other large investors also recently added to or reduced their stakes in the stock. Boston Partners increased its stake in Bruker Corporation by 12.9% in the first quarter. Boston Partners now owns 2,676,228 shares of the medical research company’s stock valued at $62,436,000 after buying an additional 305,167 shares during the last quarter. Advisory Services Network LLC bought a new stake in Bruker Corporation during the first quarter valued at approximately $150,000. Canada Pension Plan Investment Board increased its stake in Bruker Corporation by 648.9% in the first quarter. Canada Pension Plan Investment Board now owns 70,400 shares of the medical research company’s stock valued at $1,642,000 after buying an additional 61,000 shares during the last quarter. Wells Fargo & Company MN increased its stake in Bruker Corporation by 7.0% in the first quarter. Wells Fargo & Company MN now owns 849,870 shares of the medical research company’s stock valued at $19,826,000 after buying an additional 55,454 shares during the last quarter. Finally, First Quadrant L P CA increased its stake in Bruker Corporation by 11.7% in the first quarter. First Quadrant L P CA now owns 713,478 shares of the medical research company’s stock valued at $16,645,000 after buying an additional 74,807 shares during the last quarter. 67.00% of the stock is owned by institutional investors.
Shares of Bruker Corporation (NASDAQ BRKR) opened at 27.44 on Thursday. The company has a market cap of $4.38 billion, a PE ratio of 27.36 and a beta of 1.10. The company has a 50-day moving average price of $28.68 and a 200-day moving average price of $25.61. Bruker Corporation has a 1-year low of $19.59 and a 1-year high of $30.22.
Bruker Corporation (NASDAQ:BRKR) last issued its quarterly earnings results on Thursday, August 3rd. The medical research company reported $0.23 EPS for the quarter, beating analysts’ consensus estimates of $0.20 by $0.03. Bruker Corporation had a return on equity of 27.18% and a net margin of 9.65%. The firm had revenue of $414.90 million for the quarter, compared to analysts’ expectations of $384.75 million. During the same quarter in the prior year, the firm earned $0.20 EPS. The business’s revenue for the quarter was up 11.6% compared to the same quarter last year. Equities research analysts expect that Bruker Corporation will post $1.12 earnings per share for the current fiscal year.
Bruker Corporation declared that its Board of Directors has approved a share repurchase plan on Friday, May 12th that permits the company to buyback $225.00 million in outstanding shares. This buyback authorization permits the medical research company to reacquire shares of its stock through open market purchases. Shares buyback plans are often a sign that the company’s board of directors believes its shares are undervalued.
Several research firms have recently commented on BRKR. Zacks Investment Research raised Bruker Corporation from a “hold” rating to a “buy” rating and set a $33.00 price objective for the company in a report on Thursday, July 6th. Barclays PLC reissued an “equal weight” rating and issued a $30.00 price objective (up previously from $26.00) on shares of Bruker Corporation in a report on Monday, July 17th. Wells Fargo & Company downgraded Bruker Corporation from a “market perform” rating to an “underperform” rating in a report on Wednesday, July 12th. Cowen and Company reissued a “hold” rating and issued a $29.00 price objective on shares of Bruker Corporation in a report on Friday, July 14th. Finally, BidaskClub downgraded Bruker Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $27.00.
In other news, Director Ingen Chris Van sold 19,900 shares of the company’s stock in a transaction on Wednesday, June 14th. The stock was sold at an average price of $28.03, for a total transaction of $557,797.00. Following the transaction, the director now owns 14,577 shares of the company’s stock, valued at approximately $408,593.31. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Frank H. Laukien purchased 1,920 shares of the company’s stock in a transaction dated Tuesday, May 16th. The shares were purchased at an average cost of $25.88 per share, for a total transaction of $49,689.60. Following the transaction, the chief executive officer now directly owns 37,712,851 shares in the company, valued at $976,008,583.88. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 78,120 shares of company stock worth $2,047,366 and have sold 117,624 shares worth $3,271,574. 35.20% of the stock is owned by corporate insiders.
Bruker Corporation Company Profile
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Corporation (NASDAQ:BRKR).
Receive News & Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.